Outcomes of Young Adults (Aged ≤ 40 Years) with Newly Diagnosed Multiple Myeloma after Upfront Autologous Stem Cell Transplant

Multiple myeloma (MM) primarily affects older patients. There is scarce data on outcomes of young adults undergoing autologous transplantation (auto-HCT). In this single-center analysis we included 117 younger patients, with a median age of 37 years (range 22-40) at transplant. Seventeen (15%) patients had high-risk cytogenetics. Before transplant, 10% of patients achieved ≥CR and 44% achieved ≥VGPR. At best post-transplant response, 56% and 77% patients achieved ≥CR and ≥VGPR, respectively. With a median follow-up for survivors of 72.6 months (range 0.9-238.0), median PFS and OS were 43.1 months (95% CI 31.2–65.0) and 146.6 months (95% CI 100.0-208.1), respectively. Patients who underwent auto-HCT after 2010 had better median PFS (84.9 months vs. 28.2 months, p